An interventional study of Scanner of the whole body using the VECTRA 3D in Naevi, sponsored by Assistance Publique Hopitaux De Marseille. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic
The background to this research is that frequent medical screening of the general population for melanoma is not feasible. The real challenge of this project is to develop an automatic process for detecting any potential melanoma. To this end, the project aims to design an algorithm to build a novel diagnostic aid that makes use of the similarity and disparity of pigmented lesions in the same patient. To achieve this, we need to obtain and structure a large database of images grouping all pigmented lesions per patient according to their similarities as perceived by dermatologists.
47 studies on the registry are indexed under Nevus; 9 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 100 across 19 interventional studies indexed under Nevus.
Browse Nevus studies →Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma
Other: Scanner of the whole body using the VECTRA 3D
Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma
development and validation of algorithms to identify lesions clinically suspected of being melanoma by a dermatologist (potentially malignant and/or ugly duckling).
Comparison of the results given by the analysis of the images by 3 dermatologists or by the software. Estimation of sensitivity and specificity thresholds of at least 93% (accuracy level 5%).
Time frame: from enrollement to until 6 month
concordance rate for malignant annotations
concordance between the malignant yes-no annotations of each of the three dermatologists (2 to 2) will be tested.
Time frame: From enrollement to 6 month after
concordance rate for ugly duckling
concordance between the ugly duckling yes-no annotations of each of the three dermatologists (2 to 2) will be tested.
Time frame: From enrollement to 6 month after
calculation of the proportion of melanomas confirmed by anatomopathology
For each lesion identified as malignant or ugly duckling by the gold standard and removed for histological analysis: calculation of the proportion of melanomas confirmed by pathology.
Time frame: From enrollement to 6 month after
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →